Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer-Reference-Cited by-同舟云学术

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer

Published:2018-05-15 Issue:1 Volume:171 Page:65-74
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Blok Erik J.,Engels Charla C.,Dekker-Ensink Geeske,Meershoek-Klein Kranenbarg Elma,Putter Hein,Smit Vincent T. H. B. M.,Liefers Gerrit-Jan,Morden James P.,Bliss Judith M.,Coombes R. Charles,Bartlett John M. S.,Kroep Judith R.,van de Velde Cornelis J. H.,Kuppen Peter J. K.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4785-z/fulltext.html

Reference26 articles.

1. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570

2. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lonning PE, Morden J et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 30:709–717

3. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092

4. Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C et al (2017) Long-term follow-up of the intergroup exemestane study. J Clin Oncol 35(22):2507–2514

5. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. The Lancet 377:321–331

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the lymphoid tumor microenvironment (TILs) in breast cancer by flow cytometry;Medical Immunology (Russia);2024-07-27

2. The pathogenic response of cytotoxic T‑lymphocytes, a common therapeutic target for cancer, has a direct impact on treatment outcomes (Review);Oncology Reports;2024-06-17

3. Estimation of high-dimensional change-points under a group sparsity structure;Electronic Journal of Statistics;2023-01-01

4. Bootstrap Adjustment to Minimum p-Value Method for Predictive Classification;Statistica Sinica;2023

5. Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients;Cancers;2022-10-04